Arvinas, Inc.

NASDAQ:ARVN

Biotechnology

Healthcare
$6.77 -1.30%

-$0.10 today

Market cap
$443.01M
Beta
1.75
P/E (TTM)
-2.2
EPS (TTM)
-$3.46
52W Low $6.06High $14.51

Volume 1.09M

Average 0.89M

ARVN Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Arvinas, Inc.NASDAQ: ARVN

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables outflow shrinks to $0

Q1 FY2026 accounts receivables was $0, compared with $5.3M a year earlier. Trailing-twelve-month accounts receivables was $2M. Over 3 fiscal years it compounded at -19.5% a year.

Context

  • Accounts receivables amounted to 2.8% of revenue in FY2025, up 0.6 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $500K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$7.3M+228.1% YoY
LTMMar 2026
$2M+253.8% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+228.1%——
3-year CAGR-19.5%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
7.3M USD
Year-over-year change
+228.1%

Accounts Receivables vs competitors

How ARVN compares with its peers on the latest reported figures

  • ARVN's LTM Mar 2026 accounts receivables of $2M is the 3rd largest of the 6 companies compared; the peer median is $1.23M.
  • Its year-over-year change of +253.8% is the highest of 4, against a peer median of +152.2%.
  • Accounts receivables amounts to 2.2% of revenue for ARVN, versus a peer median of 2.9%.
ARVN Competitors Peer median
Accounts Receivables for ARVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KYMRKymera Therapeutics, Inc.LTM Jun 2026$20M +152.2%—19.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$5.15M -7.6%-45.1%14.8%
ARVNArvinas, Inc.LTM Mar 2026$2M +253.8%-19.5%2.2%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$1.23M +237.3%+3245.2%2.9%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$0 ——0.0%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding ARVN) $1.23M+152.2%+1600.0%2.9%

Competitors are the stored peer set for ARVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(191M)(282.5M)(367.3M)(198.9M)(80.8M)
Depreciation & Amortization6M8.2M6.7M6.6M5.2M
Deferred Income Tax00000
Stock-Based Compensation57.1M75.5M71.6M88.2M44M
Change in Working Capital678.3M(82.6M)(44.4M)(140.6M)(233.7M)
Accounts Receivables(30.2M)14M800K(5.7M)7.3M
Inventory00000
Accounts Payables27.9M20.2M17.3M(21.2M)(1.7M)
Other Working Capital680.6M(116.8M)(62.5M)(113.7M)(239.3M)
Other Non-Cash Items9M7.9M(14.4M)(14.6M)(8.5M)
Operating Cash Flow559.4M(273.5M)(347.8M)(259.3M)(273.8M)
Capital Expenditures(4.7M)(6.8M)(2.9M)(1.8M)(1.9M)
Acquisitions (Net)0400K0100K0
Purchases of Investments(1.74B)(886.4M)(956.3M)(652.1M)(354.2M)
Sales of Investments435.7M1.14B1.16B688.5M763.7M
Other Investing Activities0(400K)000
Investing Cash Flow(1.31B)242.8M203.5M34.7M407.6M
Debt Repayment000(400K)(200K)
Common Stock Issued264.6M4.7M387.2M8.3M700K
Common Stock Repurchased0000(91.9M)
Dividends Paid00000
Other Financing Activities14M0000
Financing Cash Flow278.6M4.7M374.7M7.9M(91.4M)
Effect of Forex Changes00000
Net Change in Cash(475.6M)(26M)230.4M(216.7M)42.4M
Free Cash Flow554.7M(280.3M)(350.7M)(261.1M)(275.7M)

Arvinas, Inc.

NASDAQ:ARVN

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.